Investing

Akebia Therapeutics : AKBA

AKBA

Stock Data

$1.40

$0.02 (1.45%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - SPECIALTY & GENERIC

Akebia Therapeutics Inc is a biopharmaceutical company dedicated to developing treatments for kidney diseases. Its main project, Vafseo (vadadustat), targets anemia in chronic kidney disease (CKD) patients, both those undergoing dialysis and those who are not. Additionally, Akebia offers Auryxia, a medication for managing serum phosphorus in dialysis-dependent CKD patients and treating iron deficiency anemia in non-dialysis CKD patients. The company collaborates globally, including with Mitsubishi Tanabe Pharma for vadadustat in Asia. Founded in 2007, Akebia is based in Cambridge, Massachusetts.

All Akebia Therapeutics Articles

3 Articles

Chris Lange | Mar 31, 2022 at 10:32 AM EDT

With Jobless Claims Near 50-Year Low, Analysts Upgrade and Downgrade AMD, Dell, HP and More

Thursday’s additional top analyst upgrades and downgrades included Advanced Micro Devices, Akebia Therapeutics, Dell Technologies, HP, Starwood Property Trust and…

Chris Lange | Jan 29, 2021 at 3:34 PM EST

Biogen, 3D Systems, Duke Energy, Ford and More of Friday Afternoon’s Analyst Calls

The Friday afternoon analyst calls were focused on Biogen, 3D Systems, Duke Energy, Ford, and more.

Jon C. Ogg | Sep 4, 2020 at 8:58 AM EDT

Top Analyst Upgrades and Downgrades: Akebia, Broadcom, DocuSign, Lululemon, NextEra, Overstock.com, Shopify, Wayfair and More

Friday's top analyst calls included Akebia Therapeutics, Broadcom, DocuSign, Lululemon Athletica, NextEra Energy, Overstock.com, Shopify and Wayfair.